Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sage Therapeutics

7.46
-0.3150-4.05%
Volume:590.43K
Turnover:4.43M
Market Cap:458.34M
PE:-1.13
High:7.68
Open:7.68
Low:7.41
Close:7.77
Loading ...

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Zacks
·
14 Jan

Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More

Investopedia
·
14 Jan

Sage takeout bid implies zero enterprise value, says Mizuho

TIPRANKS
·
14 Jan

Biopharmaceutical Companies Intra-Cellular and Sage Surge 34% As Drug Giants Make Acquisition Bids

Tiger Newspress
·
13 Jan

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Investopedia
·
13 Jan

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Benzinga
·
13 Jan

Sage Therapeutics Shares up 36.4% at $7.5 After Biogen Proposes to Buy Remaining Stake in Co for $7.22 Apiece

THOMSON REUTERS
·
13 Jan

Top Premarket Gainers

MT Newswires Live
·
13 Jan

Pre-Bell|U.S. Futures Slide; Tesla and Nvidia Drop 3%; MicroStrategy Sinks 5%; Moderna Plunges 17%

Tiger Newspress
·
13 Jan

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen -- Barrons.com

Dow Jones
·
13 Jan

BUZZ-Sage rises after Biogen proposes to buy remaining stake for $442 mln

Reuters
·
13 Jan

Sage Shares Surge Premarket After Biogen Proposes Takeover

Dow Jones
·
13 Jan

SAGE Therapeutics Receives Unsolicited $7.22 Per Share Acquisition Proposal From Biogen

MT Newswires Live
·
13 Jan

US Stocks to Watch: Nvidia, Tesla, Quantum-Computing Stocks, Rumble, and More

Dow Jones
·
13 Jan

Sage Stock Surges 35% After Biogen Proposes to Buy Remaining Stake for $442 Million Deal

Tiger Newspress
·
13 Jan

Sage Therapeutics Shares up 36.2% at $7.56 Premarket After Biogen Proposes to Buy Remaining Stake in Co for $7.22 Apiece

THOMSON REUTERS
·
13 Jan

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and SAGE Therapeutics (SAGE)

TIPRANKS
·
13 Jan

Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges

TIPRANKS
·
13 Jan

Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen

TIPRANKS
·
11 Jan

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal From Biogen

THOMSON REUTERS
·
11 Jan